DealsApr 13, 2026, 07:31 AM
BullFrog AI Secures Deal with Top 5 Pharma, Extends Runway to 2027
AI Summary
BullFrog AI Holdings announced a commercial feasibility agreement with a top 5 global pharmaceutical company to identify novel drug targets in major depressive disorder using its bfLEAP platform. This agreement includes milestone payments and an option for exclusive rights to a selected target. The company also secured financial runway into late 2027 and launched bfARENAS", completing its integrated AI platform for pharmaceutical R&D.
Key Highlights
- Secured commercial feasibility agreement with a top 5 global pharmaceutical company.
- Agreement focuses on identifying drug targets in major depressive disorder, a market valued at over $8 billion in 2025.
- Financial runway extended into late 2027.
- Launched bfARENAS", completing an end-to-end AI platform for R&D.